Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), successfully launched its inaugural training course in Hormonal Modulation and Gynecology, marking a significant milestone in the field of regenerative medicine. The course, held from June 10-12, 2023, in Cancun, Mexico, generated immense enthusiasm among participants as the Global Stem Cell Group demonstrated its commitment to disseminating cutting-edge training and information to medical professionals worldwide.
Led by a Well-Respected Doctor
Under the guidance of Dr. Jorge Alberto Elias, a renowned Gynecologist and Urogynecologist with over a decade of experience in Cellular Therapies, participants had the privilege of learning from a highly respected expert in the field. His expertise ensured that attendees received valuable and up-to-date information, enhancing the quality of their educational experience.
The event was divided between two esteemed venues, with the theoretical portion taking place at the Four Points Hotel, and the hands-on training conducted at the prestigious Cellular Hope Institute.
ISSCA commitment to advancing regenerative medicine was further demonstrated by the inclusion of over 30 doctors who joined the event remotely, accessing the conferences and the live proceedings through online channels. This approach enabled medical professionals worldwide to be part of the educational experience, even if they couldn’t attend in person. By embracing technology, the company expanded the reach of knowledge dissemination and fostered a global community of practitioners dedicated to staying at the forefront of regenerative medicine.
The training program focused on equipping doctors and medical professionals with the latest advancements in regenerative medicine, with a specific emphasis on gynecology. Participants delved into the cutting-edge techniques and breakthrough procedures that are shaping the field.
Three Days of Intense Learning
The three-day program was divided into theoretical sessions and hands-on practical training. The theoretical portion took place at the Four Points Hotel, where participants delved into the intricacies of hormonal modulation and its application in gynecology. Dr. Silvina Pastrana, director of ISSCA education in Latam, complemented the program with a session on Exosomes, stem cells, and automatic closed processing techniques using the GCell machine, providing a comprehensive overview of the latest advancements.
During the practical segment, participants convened at the Cellular Hope Institute, where they were immersed in real-life scenarios and witnessed the application of regenerative measures in gynecological cases. Seven diverse cases were presented, including Labiaplasty, Perineum Vaginoplasty, Lichen Sclerosus, Liposuction Mount of Venus, and Lipo fat transfer with open and closed techniques. Through these hands-on demonstrations, attendees gained practical skills and insights into utilizing regenerative medicine to enhance patients’ quality of life.
Reflecting on the success of the event, Benito Novas, Head of Public Relations for the International Society for Stem Cell Application, expressed his enthusiasm, stating, “We are delighted to further expand the ISSCA faculty and specialty areas, opening the door for all physicians to utilize the latest Regenerative Medicine technologies in their area of expertise. Our goal is to provide the best education and training in regenerative medicine and cellular therapies so that professionals can offer the highest quality care to their patients.”
ISSCA celebrates the tremendous success of this inaugural regenerative medicine training course and remains committed to expanding access to the latest knowledge and advancements in the field. By empowering medical professionals globally, ISSCA aims to help patients worldwide benefit from the latest strategies and breakthroughs in regenerative medicine.
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.